Post-Graduate Program in Medical Sciences: Endocrinology, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Faculdade de Medicina, Departamento de Medicina Interna, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Lipids Health Dis. 2022 Aug 31;21(1):83. doi: 10.1186/s12944-022-01685-z.
Despite having a 92% concentration of saturated fatty acid composition, leading to an apparently unfavorable lipid profile, body weight and glycemic effect, coconut oil is consumed worldwide. Thus, we conducted an updated systematic review and meta-analysis of randomized clinical trials (RCTs) to analyze the effect of coconut oil intake on different cardiometabolic outcomes.
We searched Medline, Embase, and LILACS for RCTs conducted prior to April 2022. We included RCTs that compared effects of coconut oil intake with other substances on anthropometric and metabolic profiles in adults published in all languages, and excluded non-randomized trials and short follow-up studies. Risk of bias was assessed with the RoB 2 tool and certainty of evidence with GRADE. Where possible, we performed meta-analyses using a random-effects model.
We included seven studies in the meta-analysis (n = 515; 50% females, follow up from 4 weeks to 2 years). The amount of coconut oil consumed varied and is expressed differently among studies: 12 to 30 ml of coconut oil/day (n = 5), as part of the amount of SFAs or total daily consumed fat (n = 1), a variation of 6 to 54.4 g/day (n = 5), or as part of the total caloric energy intake (15 to 21%) (n = 6). Coconut oil intake did not significantly decrease body weight (MD -0.24 kg, 95% CI -0.83 kg to 0.34 kg), waist circumference (MD -0.64 cm, 95% CI -1.69 cm to 0.41 cm), and % body fat (-0.10%, 95% CI -0.56% to 0.36%), low-density lipoprotein cholesterol (LDL-C) (MD -1.67 mg/dL, 95% CI -6.93 to 3.59 mg/dL), and triglyceride (TG) levels (MD -0.24 mg/dL, 95% CI -5.52 to 5.04 mg/dL). However, coconut oil intake was associated with a small increase in high-density lipoprotein cholesterol (HDL-C) (MD 3.28 mg/dL, 95% CI 0.66 to 5.90 mg/dL). Overall risk of bias was high, and certainty of evidence was very-low. Study limitations include the heterogeneity of intervention methods, in addition to small samples and short follow-ups, which undermine the effects of dietary intervention in metabolic parameters.
Coconut oil intake revealed no clinically relevant improvement in lipid profile and body composition compared to other oils/fats. Strategies to advise the public on the consumption of other oils, not coconut oil, due to proven cardiometabolic benefits should be implemented.
PROSPERO CRD42018081461.
尽管椰子油的饱和脂肪酸含量高达 92%,导致其脂质谱明显不佳,但它仍在全球范围内被食用。因此,我们进行了一项更新的系统评价和荟萃分析,以分析椰子油摄入对不同心血管代谢结局的影响。
我们在 Medline、Embase 和 LILACS 中检索了截至 2022 年 4 月之前进行的随机临床试验(RCT)。我们纳入了比较椰子油摄入与其他物质对成年人的体重和血糖影响的 RCT,研究语言不限,并排除了非随机试验和随访时间较短的研究。使用 RoB 2 工具评估偏倚风险,使用 GRADE 评估证据确定性。在可能的情况下,我们使用随机效应模型进行荟萃分析。
我们的荟萃分析纳入了 7 项研究(n=515;女性占 50%,随访时间 4 周至 2 年)。椰子油的摄入量不同,且在不同研究中的表达方式也不同:12 至 30 毫升/天(n=5)、作为 SFA 或总日消耗脂肪的一部分(n=1)、6 至 54.4 克/天(n=5),或作为总热量摄入的一部分(15%至 21%)(n=6)。椰子油摄入并没有显著降低体重(MD-0.24 公斤,95%CI-0.83 公斤至 0.34 公斤)、腰围(MD-0.64 厘米,95%CI-1.69 厘米至 0.41 厘米)和体脂肪百分比(-0.10%,95%CI-0.56%至 0.36%)、低密度脂蛋白胆固醇(LDL-C)(MD-1.67 毫克/分升,95%CI-6.93 毫克/分升至 3.59 毫克/分升)和甘油三酯(TG)水平(MD-0.24 毫克/分升,95%CI-5.52 毫克/分升至 5.04 毫克/分升)。然而,椰子油摄入与高密度脂蛋白胆固醇(HDL-C)水平的轻微升高相关(MD3.28 毫克/分升,95%CI0.66 毫克/分升至 5.90 毫克/分升)。整体偏倚风险较高,证据确定性为极低。研究局限性包括干预方法的异质性,以及小样本量和短随访时间,这些因素削弱了饮食干预对代谢参数的影响。
与其他油/脂肪相比,椰子油摄入对血脂谱和身体成分没有明显的临床改善作用。应该实施策略,建议公众不要食用椰子油,而应选择其他已被证明具有心血管代谢益处的油。
PROSPERO CRD42018081461。